异动解读｜BioNTech SE盘中下跌8.22%，终止癌症免疫疗法试验叠加新冠疫苗适用人群收窄

行情直击08-28

8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。

消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上成年人和5至64岁高风险人群，较此前面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。双重利空叠加，公司上一季度净亏损高达8.208亿欧元的基本面，令投资者信心明显受挫。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1100503819?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-28 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100503819","market":"hk","top_or_hot":-1,"title":"异动解读｜BioNTech SE盘中下跌8.22%，终止癌症免疫疗法试验叠加新冠疫苗适用人群收窄","media":"行情直击","content":"<p><p>8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。</p><p>消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上成年人和5至64岁高风险人群，较此前面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。双重利空叠加，公司上一季度净亏损高达8.208亿欧元的基本面，令投资者信心明显受挫。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜BioNTech SE盘中下跌8.22%，终止癌症免疫疗法试验叠加新冠疫苗适用人群收窄</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜BioNTech SE盘中下跌8.22%，终止癌症免疫疗法试验叠加新冠疫苗适用人群收窄\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-28 21:32 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"1100503819","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100503819","pubTimestamp":1787923929,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上成年人和5至64岁高风险人群，较此前面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"Analysis of Unusual Movements | BioNTech SE fell 8.22% intraday after terminating cancer immunotherapy trials and narrowing the population eligible for COVID-19 vaccines.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上成年人和5至64岁高风险人群，较此前面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。双重利空叠加，公司上一季度净亏损高达8.208亿欧元的基本面，令投资者信心明显受挫。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100503819","isCrawlerRequest":true}